SecBot SecBot
DEFA14A8-K ·Filed Aug 20, 2026

HSCS

HeartSciences Inc.
BULLISH
Impact 5/10
Horizonweeks Processed2mo ago SEC0001213900-26-091895
Actionable Insight ▲ Bullish

The $1M private placement at a premium and Fortitude's strong Q2 results reduce near-term financing risk for HSCS while the merger progresses. Monitor for the definitive proxy statement and shareholder vote timeline — the key catalyst is the merger close, expected H2 2026. The unchanged exchange ratio means HSCS shareholders' relative position in the combined entity is preserved.

DirectionBullish
Confidencehigh
Horizonweeks
Latest settled — T+20d
HSCS ▲ +92.83% at T+20d
LONG call ✓ call won +92.83% · α vs SPY +92.83% · entry $2.51 → $4.84
Next anchor: T+60d in 18d
Latest observation: T+45 +6.21% FF3 residual α
Entry = T+0 close
Aug 20, 2026
via day close
T+1d
+11.55%
call +11.55% · α +11.14%
$2.80
settled 2mo ago
T+5d
+24.30%
call +24.30% · α +23.19%
$3.12
settled 2mo ago
T+20d
+92.83%
call +92.83% · α +92.83%
$4.84
settled 5w ago
T+60d
Pending
in 18d

Price Chart

Loading chart...

Executive Summary

HeartSciences (HSCS) filed an 8-K and DEFA14A disclosing that its merger partner, Fortitude Mining, reported strong Q2 2026 results with $20.9M revenue and $8.5M Adjusted EBITDA. More importantly, Fortitude purchased ~$1M of HSCS common stock at a 22% premium ($2.43/share) on August 12, 2026, acquiring a 9.4% stake. This capital infusion supports HSCS's operating expenses ahead of the proposed business combination, which is expected to close in H2 2026. The investment signals Fortitude's commitment to the deal but does not change the exchange ratio or provide additional shares at closing, making it a modest positive for HSCS shareholders as it reduces near-term cash burn risk while the merger proceeds.

Key Facts

  • Fortitude reported Q2 2026 revenue of $20.9 million and Adjusted EBITDA of $8.5 million.
  • Fortitude purchased 411,522 shares of HSCS common stock at $2.43/share (22% premium to market) for approximately $1,000,000.
  • Fortitude now owns approximately 9.4% of HSCS's outstanding common stock.
  • The proposed business combination between Fortitude and HeartSciences is expected to close in H2 2026.
  • The exchange ratio under the merger agreement is unchanged; Fortitude receives no additional shares at closing from this subscription.

Financial Impact

Fortitude invested approximately $1,000,000 in HSCS at a 22% premium, providing near-term operating capital. Fortitude's Q2 revenue of $20.9M and Adj. EBITDA of $8.5M demonstrate strong cash generation from the mining operations that will become the public company post-merger.

cashdilutionownership

Risk Factors

  • Merger may not close on anticipated timeline or at all, requiring shareholder approval.
  • Fortitude's operations are tied to highly volatile cryptocurrency (Zcash) prices and hash rates.
  • HSCS's standalone business has minimal revenue; post-merger valuation depends on Fortitude's crypto mining performance.

Market Snapshot

Exchange
Nasdaq
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (HSCS) — Batch item 10001213900-26-091895
Document: ea0302835-8k_heart.htm0001213900-26-091893
Document: 0001213900-26-091895-index-headers.html0001213900-26-091895
Document: 0001213900-26-091895-index.html0001213900-26-091895
Document: 0001213900-26-091895.txt0001213900-26-091895
8-K Filing (HSCS) — Batch item 60001213900-26-091893
Document: ea0302835-8k_heart.htm0001213900-26-091895
Document: 0001213900-26-091893-index-headers.html0001213900-26-091895
Document: 0001213900-26-091893-index.html0001213900-26-091895
Document: 0001213900-26-091893.txt0001213900-26-091895
50 reports for HSCS
Performance horizon
67% Hit rate @ T+1 4 of 6 directional calls Went positive at some point 5 of 6 best @ T+60▲ +46.76%Jul 29, 2026
Filters
Rows
Reports for HSCS — sortable, filterable
TypeNow
Oct 26, 2026
today
DEFA14A
NEUTRAL ★ 4/10
—awaiting T+1——
Oct 23, 2026
2d ago
SC 13D/A
NEUTRAL ★ 3/10
$3.41awaiting T+1—$3.18 (−6.74%)
Oct 21, 2026
5d ago
DEFA14A
NEUTRAL ★ 5/10
$3.17 $3.14▼ −0.95%▼ −0.42%$3.18 (+0.32%)
Oct 19, 2026
7d ago
DEFA14A
NEUTRAL ★ 3/10
$3.13 $3.56▲ +13.74%▲ +13.21%$3.18 (+1.60%)
Oct 19, 2026
7d ago
DEFA14A
NEUTRAL ★ 3/10
$3.07 $3.13▲ +1.95%▲ +1.62%$3.18 (+3.58%)
Oct 19, 2026
7d ago
DEFM14A
BEARISH ★ 7/10
$3.07 $3.13▼ −1.95%▼ −1.62%$3.18 (−3.58%)
Oct 15, 2026
10d ago
DEFA14A
NEUTRAL ★ 4/10
$3.02 $3.07▲ +1.66%▲ +1.23%$3.18 (+5.30%)
Oct 9, 2026
16d ago
424B5
BEARISH ★ 5/10
$3.30 $3.09▲ +6.36%▲ +6.35%$3.18 (+3.64%)
Oct 6, 2026
20d ago
DEFA14A
MIXED ★ 5/10
$3.49 $3.04▼ −12.89%▼ −12.47%$3.18 (−8.88%)
Oct 6, 2026
20d ago
8-K
NEUTRAL ★ 4/10
$3.49 $3.04▼ −12.89%▼ −12.47%$3.18 (−8.88%)
Showing 10 of 50

US Market Status

Market Closed — Opens Tue (16h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 20, 2026